Alnylam Pharmaceuticals, Inc. financial reports, Alnylam Pharmaceuticals, Inc. annual revenue in 2024. When does Alnylam Pharmaceuticals, Inc. report revenue?
Alnylam Pharmaceuticals, Inc. total revenue, net income and dynamics of changes in US dollar today
Alnylam Pharmaceuticals, Inc. current income in US dollar. The dynamics of Alnylam Pharmaceuticals, Inc. net revenue has changed by 14 004 000 $ over the last period. Alnylam Pharmaceuticals, Inc. net income is now -200 291 000 $. The financial report chart shows the values from 30/06/2017 to 31/03/2021. Alnylam Pharmaceuticals, Inc. financial report on the graph shows the dynamics of assets. All information on Alnylam Pharmaceuticals, Inc. total revenue on this chart is created in the form of yellow bars.
Report date
Total revenue
Total revenue refers to the total receipts from sales of a given quantity of goods or services. It is the total income of a business and is calculated by multiplying the quantity of goods sold by the price of the goods.
and
Change (%)
Comparing current quartal report this year to quartal report last year.
Net income
Net income is an entity's income minus cost of goods sold, expenses and taxes for an accounting period.
and
Change (%)
Comparing current quartal report this year to quartal report last year.
31/03/2021
177 566 000 $
+433.33 % ↑
-200 291 000 $
-
31/12/2020
163 562 000 $
+128.18 % ↑
-243 540 000 $
-
30/09/2020
125 853 000 $
+79.63 % ↑
-253 291 000 $
-
30/06/2020
103 962 000 $
+132.5 % ↑
-179 229 000 $
-
31/12/2019
71 681 000 $
-
-276 185 000 $
-
30/09/2019
70 061 000 $
-
-208 535 000 $
-
30/06/2019
44 714 000 $
-
-219 481 000 $
-
31/03/2019
33 294 000 $
-
-181 915 000 $
-
31/12/2018
21 033 000 $
-
-211 441 000 $
-
30/09/2018
2 069 000 $
-
-245 282 000 $
-
30/06/2018
29 907 000 $
-
-163 560 000 $
-
31/03/2018
21 899 000 $
-
-141 214 000 $
-
31/12/2017
37 924 000 $
-
-142 227 000 $
-
30/09/2017
17 096 000 $
-
-122 937 000 $
-
30/06/2017
15 932 000 $
-
-118 420 000 $
-
Show:
to
Alnylam Pharmaceuticals, Inc. financial report charts
Dates of Alnylam Pharmaceuticals, Inc. finance reports: 30/06/2017, 31/12/2020, 31/03/2021. The dates of the financial statements are determined by the accounting rules. The latest date of the financial report of Alnylam Pharmaceuticals, Inc. is 31/03/2021. Gross profit Alnylam Pharmaceuticals, Inc. is the profit a company makes after deducting the costs of making and selling its products, or the costs of providing its services. Gross profit Alnylam Pharmaceuticals, Inc. is 146 504 000 $
Alnylam Pharmaceuticals, Inc. quarterly report dates
Cost of revenue Alnylam Pharmaceuticals, Inc. is the total cost of producing and distributing of products and services of a company. Cost of revenue Alnylam Pharmaceuticals, Inc. is 31 062 000 $ Total revenue Alnylam Pharmaceuticals, Inc. refers to the total receipts from sales of a given quantity of goods or services. It is the total income of a business and is calculated by multiplying the quantity of goods sold by the price of the goods. Total revenue Alnylam Pharmaceuticals, Inc. is 177 566 000 $ Operating income Alnylam Pharmaceuticals, Inc. is an accounting figure that measures the amount of profit realized from a business's operations, after deducting operating expenses such as wages, depreciation and cost of goods sold (COGS). Operating income Alnylam Pharmaceuticals, Inc. is -186 254 000 $
Net income Alnylam Pharmaceuticals, Inc. is an entity's income minus cost of goods sold, expenses and taxes for an accounting period. Net income Alnylam Pharmaceuticals, Inc. is -200 291 000 $ Current assets Alnylam Pharmaceuticals, Inc. is a balance sheet item that represents the value of all assets that can reasonably expect to be converted into cash within one year. Current assets Alnylam Pharmaceuticals, Inc. is 2 470 083 000 $ Total assets Alnylam Pharmaceuticals, Inc. refers to the total amount of assets owned by a person or entity. Total assets Alnylam Pharmaceuticals, Inc. is 3 255 269 000 $
31/03/2021
31/12/2020
30/09/2020
30/06/2020
31/12/2019
30/09/2019
30/06/2019
31/03/2019
31/12/2018
30/09/2018
30/06/2018
31/03/2018
31/12/2017
30/09/2017
30/06/2017
Gross profit
Gross profit is the profit a company makes after deducting the costs of making and selling its products, or the costs of providing its services.
146 504 000 $
140 538 000 $
104 056 000 $
84 033 000 $
59 505 000 $
64 848 000 $
40 388 000 $
29 947 000 $
19 368 000 $
1 932 000 $
29 907 000 $
-
-
-
-
Cost of revenue
Cost of revenue is the total cost of producing and distributing of products and services of a company.
31 062 000 $
23 024 000 $
21 797 000 $
19 929 000 $
12 176 000 $
5 213 000 $
4 326 000 $
3 347 000 $
1 665 000 $
137 000 $
-
-
-
-
-
Total revenue
Total revenue refers to the total receipts from sales of a given quantity of goods or services. It is the total income of a business and is calculated by multiplying the quantity of goods sold by the price of the goods.
177 566 000 $
163 562 000 $
125 853 000 $
103 962 000 $
71 681 000 $
70 061 000 $
44 714 000 $
33 294 000 $
21 033 000 $
2 069 000 $
29 907 000 $
21 899 000 $
37 924 000 $
17 096 000 $
15 932 000 $
Operating revenue
Operating revenue is revenue generated from a company's primary business activities. For example, a retailer produces revenue through merchandise sales, and a physician derives revenue from the medical services he/she provides.
-
-
-
-
71 681 000 $
70 061 000 $
44 714 000 $
33 294 000 $
21 033 000 $
2 069 000 $
29 907 000 $
21 899 000 $
37 924 000 $
17 096 000 $
15 932 000 $
Operating income
Operating income is an accounting figure that measures the amount of profit realized from a business's operations, after deducting operating expenses such as wages, depreciation and cost of goods sold (COGS).
-186 254 000 $
-194 222 000 $
-225 199 000 $
-198 859 000 $
-298 073 000 $
-216 299 000 $
-236 271 000 $
-188 788 000 $
-220 356 000 $
-254 558 000 $
-192 354 000 $
-147 405 000 $
-147 303 000 $
-125 800 000 $
-120 474 000 $
Net income
Net income is an entity's income minus cost of goods sold, expenses and taxes for an accounting period.
-200 291 000 $
-243 540 000 $
-253 291 000 $
-179 229 000 $
-276 185 000 $
-208 535 000 $
-219 481 000 $
-181 915 000 $
-211 441 000 $
-245 282 000 $
-163 560 000 $
-141 214 000 $
-142 227 000 $
-122 937 000 $
-118 420 000 $
R&D spending
Research and Development spending - cost of investigative activities to improve existing products and procedures or to lead to the development of new products and procedures.
166 623 000 $
150 358 000 $
143 527 000 $
137 295 000 $
185 106 000 $
147 746 000 $
150 712 000 $
116 900 000 $
118 923 000 $
128 134 000 $
126 900 000 $
96 857 000 $
117 772 000 $
95 252 000 $
90 627 000 $
Operating expense
An operating expense is an expenditure that a business incurs as a result of performing its normal business operations.
363 820 000 $
357 784 000 $
351 052 000 $
302 821 000 $
369 754 000 $
286 360 000 $
280 985 000 $
222 082 000 $
241 389 000 $
256 627 000 $
222 261 000 $
169 304 000 $
185 227 000 $
142 896 000 $
136 406 000 $
Current assets
Current assets is a balance sheet item that represents the value of all assets that can reasonably expect to be converted into cash within one year.
2 470 083 000 $
2 614 777 000 $
2 554 702 000 $
2 160 446 000 $
1 715 864 000 $
1 897 265 000 $
2 063 773 000 $
1 392 013 000 $
1 200 696 000 $
1 342 120 000 $
1 502 559 000 $
1 685 297 000 $
1 764 740 000 $
993 368 000 $
960 709 000 $
Total assets
Total assets refers to the total amount of assets owned by a person or entity.
3 255 269 000 $
3 407 061 000 $
3 307 283 000 $
3 374 367 000 $
2 395 134 000 $
2 541 622 000 $
2 716 411 000 $
2 013 999 000 $
1 574 802 000 $
1 675 654 000 $
1 789 389 000 $
1 923 139 000 $
1 994 730 000 $
1 358 281 000 $
1 434 283 000 $
Current cash
Current cash - the sum of all of the cash a company has on the date of report.
379 543 000 $
496 580 000 $
496 704 000 $
580 829 000 $
547 178 000 $
923 304 000 $
1 136 289 000 $
724 959 000 $
420 146 000 $
316 608 000 $
361 457 000 $
397 876 000 $
645 361 000 $
202 045 000 $
408 671 000 $
Current debt
Current debt is the portion of debt due within a year (12 months) and is listed as a current liability and part of net working capital.
-
-
-
-
352 594 000 $
352 864 000 $
328 604 000 $
149 163 000 $
179 494 000 $
121 503 000 $
113 659 000 $
-
-
-
-
Total cash
Total cash - the sum of all of the cash a company has on its books, including petty cash and funds on deposit in a bank.
-
-
-
-
-
-
-
-
-
-
-
1 567 864 000 $
1 690 618 000 $
948 294 000 $
923 271 000 $
Total debt
Total debt is a combination of both short-term and long-term debt. Short-term debts are those that must be paid back within a year. Long-term debt generally includes every liability that must be paid off in more than a year.
-
-
-
-
956 442 000 $
934 535 000 $
959 216 000 $
467 013 000 $
272 837 000 $
197 535 000 $
168 587 000 $
-
-
-
-
Debt ratio
Total debt to total assets - is a financial ratio that indicates the percentage of a company's assets that are provided via debt.
-
-
-
-
39.93 %
36.77 %
35.31 %
23.19 %
17.33 %
11.79 %
9.42 %
-
-
-
-
Shareholders equity
Shareholder's equity (SE) is the owner's claim after subtracting total liabilities from total assets.
926 190 000 $
1 016 247 000 $
1 215 023 000 $
1 399 726 000 $
1 438 692 000 $
1 607 087 000 $
1 757 195 000 $
1 546 986 000 $
1 301 965 000 $
1 478 119 000 $
1 620 802 000 $
1 754 805 000 $
1 766 431 000 $
1 058 835 000 $
1 122 966 000 $
Cash flow
Cash flow is the net amount of cash and cash-equivalents being transferred into and out of a business.
-
-
-
-
-195 980 000 $
-182 632 000 $
288 695 000 $
-188 510 000 $
-150 457 000 $
-153 808 000 $
-102 687 000 $
-155 664 000 $
-103 044 000 $
-98 363 000 $
-81 049 000 $
Last revenue report of Alnylam Pharmaceuticals, Inc. was 31/03/2021. According to last financial report total revenue in Alnylam Pharmaceuticals, Inc. was 177 566 000 US dollar and changed by +433.33% since last year. Net income in Alnylam Pharmaceuticals, Inc. was -200 291 000 $ in last quartal, net income changes to 0%.
Current cash Alnylam Pharmaceuticals, Inc. - the sum of all of the cash a company has on the date of report. Current cash Alnylam Pharmaceuticals, Inc. is 379 543 000 $
Alnylam Pharmaceuticals, Inc. stocks data
ALNY stock price
Alnylam Pharmaceuticals, Inc. stock price today, ALNY stock quote.
